Hemispherx Biopharma (HEB) Wins Federal Lawsuit Regarding Investment Banking Fees
3/10/2014 9:51:04 AM
PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company"or "Hemispherx"), announced that after more than a week in trial, a federal jury in Atlanta took only an hour to determine there was no merit to a brokerage firm's claim that Hemispherx owed the firm over $6 million for commissions from private sales of stock in 2009.
Help employers find you! Check out all the jobs and post your resume.
comments powered by